Torrent Pharma ‘retired hurt’ from drug discovery, but not out yet: Aman Mehta

Torrent Pharma has decided to pause its aggressive push into new drug discovery. The company, which has historically invested heavily in research and development, is now shifting its focus. Instead of building new molecules from scratch, it plans to invest in acquiring established assets and technologies. This strategic pivot aims to secure a faster return on investment and reduce the inherent risks associated with long, uncertain research cycles.

This move is significant for investors as it signals a change in Torrent’s capital allocation strategy. By prioritizing acquisitions, the company is betting on a more predictable path to growth. It reflects a broader trend among large pharma firms to optimize their portfolios. While this reduces the potential for high-risk, high-reward breakthroughs, it provides a more stable foundation for earnings in the near term.

Investors should watch how Torrent integrates its new acquisitions and manages its existing portfolio. The success of this strategy will depend on the company's ability to efficiently integrate new assets and maintain its market share. It is also important to monitor the company's guidance on future capital deployment to see if this shift is permanent or a temporary adjustment.